Bordeaux, France — December 3, 2025. A month after receiving the 10x Genomics’ « Certified Service Provider » designation across Xenium, Visium HD, and Chromium X, Explicyte, a French precision oncology contract research organization (CRO), today announced that it has doubled its capacity in single-cell spatial biology with the acquisition of a second Xenium platform.
Explicyte acquired its first Xenium platform in October 2024 to accelerate the discovery of novel targets and biomarkers, and support drug development programmes in oncology through single-cell spatial transcriptomics.
Within a year, the company profiled more than 150 tissue specimens with Xenium, doubled its data science team, announced a partnership with Cure51 for the analysis of tumor samples from exceptional cancer survivors, and developed new methods to use Xenium in the context of cell-based assays.
“Despite optimizing the number of samples per run, we still reached our maximum capacity very quickly over 2025. To be able to offer additional slots and ensure fast turnaround times, we needed a second Xenium » said Jean-Philippe Guégan, PhD, Chief Technology Officer at Explicyte. « Our sponsors in the pharma, biotech and AI industry can’t delay their programmes — they look for availability, throughput, and robust data. With this new infrastructure, our message is clear: if you need Xenium data fast and in line with industry standards, Explicyte is your partner of choice.”
About Explicyte
Explicyte is a preclinical and translational contract research organization specializing in precision oncology. Founded in 2015 by immunologist Dr. Alban Bessède, the company has supported over 100 biotech and pharmaceutical partners in the discovery and development of novel therapies for solid tumors. Based at the Institut Bergonié Comprehensive Cancer Center in Bordeaux, Explicyte brings together a multidisciplinary team of 25 scientists, including cell biologists, digital pathologists, medical oncologists, and data scientists. Over the past five years, Explicyte has co-authored 30+ peer-reviewed publications on the molecular mechanisms of response to cancer immunotherapies.
For more information, visit www.explicyte.com
Press contacts
Explicyte – Pierre-Emmanuel GAULTIER – pe.gaultier@explicyte.com – +33 6 450 600 49